Overview

Study on Safety, Absorption and Metabolism of SYHA1402 Tablets in Healthy People

Status:
Completed
Trial end date:
2020-01-14
Target enrollment:
Participant gender:
Summary
The trial used single-center, randomized, double-blind, placebo-controlled, single-dose study. The trial planned to enroll sixty-two healthy volunteers. The subjects were allocated to seven dose groups, including 25 mg (4+2), 50 mg (8+2), 100 mg (8+2), 200 mg (8+2), 400 mg (8+2), 800 mg (6+2) and 1200 mg (6+2). Each dose group was allocated test drugs and placebos according to the proportion of subjects in the brackets mentioned above.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.